Develop of Adolscenta

                                                 Field Research

                                            LaBretta Gregory

                                          July 13, 2015

                                           PSYCH/600

                                           Deborah Wilkerson

   This research paper will discuss how Strattera product claim to enhance, and how the published

Literature say about the issues or concerns of Strattera. It will also discuss what the research will

reveal about how the promote a healthy development in this area, and the benefits of the product.

It will also, show evidence to support this claim. Strattera is a non-stimulant medication, and

Strattera is also a non-stimulant medication for treatment of distractibility, impulsivity, and

hyperactivity in children, teens, with ADHD/ADD.

   According to Larry Silver M.D., states that Strattera was advertised as the first non-stimulant  

medication for ADHD/ADD, but there are several non-stimulant medication for ADHD/ADD

such as tri-cyclic antidepressants, which is also prescribe to treat attention-deficit/hyperactivity

disorder. Strattera is approved for children aged 6 years and older, and the safety and the

effectiveness has not been established in patients less than six years of age (Larry Silver M.D.

2011).

   According to Food and Drug Administration (FDA), issue today is issuing a Public Health

Advisory to alert the physicians of the reports of suicidal thinking in children who have been

associated with taking Strattera, which is a approved drug to treat children with ADHD.

According to the FDA, they directed Eli Lilly & Company, and the manufacturer of Strattera

to develop a Medication Guide for patient’s and caregivers. Food and Drug Administration is

also advising the health care providers and care givers of the children and adolescents being

treated with Strattera should be monitored closely for worsening, agitation, irritability, and

have suicidal thinking or behavior problems, during the first few months of therapy or when their

doses are changed.

  According to Dr. Steven Galson, for the “Center for Drug Evaluation and Research, FDA,

states that it has been one suicidal attempt by a patient who was taking Strattera, among the

2,200 patients in the trail. FDA have requested the manufacturer of Strattera to conduct their

Database of their clinical trail’s, which includes 2,200 patients, and 1,250 patients received

Strattera, and 851 patients received placebo. After running their database it showed only 0.4%

children were treated with Strattera, and reported suicidal thinking that compared to no cases

in children with placebo. Strattera have been on the market since 2002, and have been used by

more than two million patients (FDA, 2005).

    Research may use music to promote a healthy development in this area. Research think using

music will promote the knowledge on how participants may use in this new area of technology

to learn about new materials and practice methods. Research reveals that music is a motivational

device for relaxing our bodies, it release stress or aggression. Researchers implementation in the

future health promotion and rehabilitation programs should strengthen their focus on the musical,

cultural, and physical activity on an individual level (Kari Batt-Rawden. 2005).